



## ASX RELEASE

### Closure of Rights Issue

**Melbourne, Australia, 20 December 2019:** [Sienna Cancer Diagnostics Ltd \(ASX:SDX\)](#) (“Sienna” or “the Company”), a medical technology company developing and commercialising innovative IVD tests, advises that the Non-Renounceable Rights Issue Offer (**Rights Issue**), announced 29 November 2019, closed Tuesday 17 December 2019.

The Rights Issue provided eligible shareholders with the opportunity to purchase new ordinary shares at the same price as the recently completed Placement to institutional and sophisticated investors - 3.5 cents per share. Shareholders were provided an option to apply for additional shares in excess of their Rights Issue entitlement. The directors have determined that those shareholders who have applied for additional shares have their application accepted in full. A total of \$262,587.62 was raised from existing shareholders, representing 7,616,789 shares.

Funds raised to date from the Placement and Rights Issue total \$1.9 million.

Prior to launching the Rights Issue Offer the Company entered into an agreement with Merchant Corporate Advisory Pty Ltd (Merchant) to place shortfall shares with institutional and sophisticated investors on a best endeavours basis. Merchant has indicated that they will place a substantial proportion of the shortfall, however, due to proximity of the festive season the allocation of shares is likely to occur in the week commencing 6 January 2020.

Sienna’s CEO and Managing Director, Carl Stubbings, commented “We appreciate the continued support of our shareholders. These funds, combined with new capital received via the Placement, will enable us to continue to execute the SIEN-NET™ commercialisation strategy, underpinning the current collaborations with Minomic and Vivazome, and to continue to actively seek new collaborations for this ground-breaking technology”.

The allotment of new shares to existing shareholders under the Rights Issue will occur in accordance with the Rights Issue timetable included in the announcement of 29 November 2019.

ENDS.

**For further information, please contact:**

Geoffrey Cumming, Chairman  
Sienna Cancer Diagnostics Ltd  
[cstubblings@siennadiagnostics.com.au](mailto:cstubblings@siennadiagnostics.com.au)  
+61 3 8288 2141

Carl Stubbings, CEO/Managing Director  
Sienna Cancer Diagnostics Ltd  
[tdipietro@siennadiagnostics.com.au](mailto:tdipietro@siennadiagnostics.com.au)  
+61 3 8288 2141

The release of this announcement was authorised by Tony Di Pietro, Company Secretary



### **About Sienna Cancer Diagnostics**

Sienna Cancer Diagnostics Ltd is an Australian medical technology company with operations in the United States, Europe, Asia, Latin America and Australia. Sienna's strengths lie in the identification, development and commercialisation of novel IVD technologies that satisfy an unmet clinical / market need. The Company has taken its first product, an IVD test for the biomarker hTERT, from research, through development, manufacturing, product registration, and market launch through a growing network of distribution partners.

The Company is focused on growing revenues from the existing product, increasing market access through new distribution partners, extending the applications for their hTERT test, and expanding their product offerings with the addition of new technologies into the product development pipeline.

Sienna's most recent technology acquisition was a unique technology for the capture and isolation of target analytes in liquid biopsy samples. The sample preparation technology, known as SIEN-NET™, can more accurately and rapidly prepare samples for the liquid biopsy testing of a range of clinically useful biomarkers including exosomes, lipids, proteins, and other molecular targets of interest.

### **Forward Looking Statements**

This announcement may contain forward-looking statements, which include all matters that are not historical facts. These forward-looking statements speak only as at the date of this announcement. These statements, by their nature, are subject to a number of known and unknown risks and uncertainties that could cause the actual results, performances and achievements to differ materially from any expected future results, performance or achievements expressed or implied by forward-looking statements. Without limitation, indications of, and guidance on, future earnings and financial position and performance are examples of forward-looking statements. No representation, warranty or assurance (express or implied) is given or made by Sienna that the forward-looking statements contained in this announcement are accurate, complete, reliable, or adequate or that they will be achieved or prove to be correct. Except for any statutory liability which cannot be excluded, each of Sienna, its related companies and their respective directors, employees and advisers expressly disclaim any responsibility for the accuracy or completeness of the forward looking statements and exclude all liability whatsoever (including negligence) for any direct or indirect loss or damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom.